IL18 and diabetes mellitus: Moreover, dapagliflozin inhibited the expression of NLRP3, ASC, caspase-1, IL-1β, and IL-18 in DM mice, and such expression was also decreased in the nondiabetic atherosclerosis model (not statistically significant).